Legend Biotech Director Awarded 28,330 Share Units

One-third vests December 20, 2027, with the remainder in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.

Rhea-AI Filing Summary

Legend Biotech Corp director Peter Salovey received an award of 28,330 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027; the remainder vest in 12 equal quarterly installments beginning on March 20, 2028, subject to his continued service on each vesting date. His reported direct holding following the transaction was 55,096 ordinary shares.

Insider Trade Summary

Grant/Award: 28,330 shares

Grant/Award 1 txn

Insider Salovey Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2	28,330	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 55,096 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

RSUs awarded: 28,330 restricted share units Direct holding after transaction: 55,096 ordinary shares Initial vesting portion: 1/3 of the RSUs +1 more

4 metrics

RSUs awarded 28,330 restricted share units Awarded September 24, 2026

Direct holding after transaction 55,096 ordinary shares Reported following the transaction

Initial vesting portion 1/3 of the RSUs Vests December 20, 2027, subject to continued service

Remaining vesting installments 12 equal quarterly installments Beginning March 20, 2028, subject to continued service

Key Terms

restricted share units (RSUs), contingent right, settlement, American Depositary Shares (ADSs)

4 terms

restricted share units (RSUs) financial

"Represents restricted share units (the "RSUs")"

Restricted share units (RSUs) are a form of employee pay where a company promises to give shares (or their cash value) to workers after certain conditions, usually time or performance, are met. For investors, RSUs matter because they can increase the number of shares outstanding and signal how management is being paid and incentivized—think of them as delayed bonuses that convert into ownership when vesting conditions are satisfied.

contingent right financial

"Each RSU represents a contingent right"

settlement financial

"upon settlement"

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

American Depositary Shares (ADSs) financial

"may be represented by American Depositary Shares"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was Peter Salovey's Legend Biotech RSU award?

Peter Salovey received an award of 28,330 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 04:10 PM Accepted by SEC EDGAR 09/28/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salovey Peter

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

77 CORPORATE DRIVE, 4TH FLOOR

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/24/2026		A		28,330(2)	A	$0	55,096	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Robert Staloff, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)